Abraham Weizman holds an M.D. degree. He is the Director of Research at the Geha Mental Health Center and of the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, and a Professor of psychiatry at the Sackler Faculty of Medicine, Tel-Aviv University, Israel. He is also a holder of the Robert and Martha Härdén Chair in Mental and Neurological Diseases. Professor Weizman specializes in both adult and child psychiatry. His research focuses on the neurobiology and neurogenetics of mental disorders along human development. In recent years, he demonstrated the role of specific alleles of the gene for the serotonin transporter, in the pharmacological response to the antidepressant citalopram of anxious and depressed children and adolescents. In addition, he characterized the gene-psychiatric symptomatology in velocardiofacial syndrome. He also developed a new antipsychotic agent (BL-1020) that is currently under worldwide clinical trials, for the treatment of schizophrenia. Professor Weizman has published over 600 original papers in the field of neuropsychobiology as well as multiple chapters in books, over 50 review articles, and over 30 case studies. He also edited 5 books in his field.
Biography Updated on 19 December 2011